OXC-101 is under clinical development by Oxcia and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how OXC-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

OXC-101 overview

OXC-101 (TH-1579/Karonudib) is under investigation for the treatment of metastatic melanoma, relapsed and refractory acute lymphocytic leukemia, acute myeloid leukemia, diffuse large B-cell lymphoma, burkitt lymphoma, multiple myeloma, myelodysplastic syndrome and solid malignant tumors. The drug candidate is administered through oral route as a solution. It acts by targeting 7,8-dihydro-8-oxoguanine triphosphatase (MTH1).

Oxcia overview

Oxcia is a pharmaceutical manufacturing company. Oxcia is headquartered in Stockholm, Sweden.

For a complete picture of OXC-101’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.